Strides Pharma Science (NSE:STAR) Total Liabilities : ₹37,746 Mil (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Strides Pharma Science Total Liabilities?

Strides Pharma Science's Total Liabilities for the quarter that ended in Sep. 2024 was ₹37,746 Mil.

Strides Pharma Science's quarterly Total Liabilities declined from Mar. 2024 (₹37,680.49 Mil) to Jun. 2024 (₹0.00 Mil) but then increased from Jun. 2024 (₹0.00 Mil) to Sep. 2024 (₹37,746.31 Mil).

Strides Pharma Science's annual Total Liabilities declined from Mar. 2022 (₹45,925.46 Mil) to Mar. 2023 (₹44,655.37 Mil) and declined from Mar. 2023 (₹44,655.37 Mil) to Mar. 2024 (₹37,680.49 Mil).

Strides Pharma Science Total Liabilities Historical Data

The historical data trend for Strides Pharma Science's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Total Liabilities Chart

Strides Pharma Science Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

35,570.78

42,010.18

45,925.46

44,655.37

37,680.49

Strides Pharma Science Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															43,442.85	-	37,680.49	-	37,746.31

Strides Pharma Science Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Strides Pharma Science's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28792.59	+	(7431.34	+	1456.56
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	37,680

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	58397.55	-	20717.06
	=	37,680

Strides Pharma Science's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	29639.13	+	(6394.99	+	1712.19
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	37,746

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	59896.29	-	22149.98
	=	37,746

Strides Pharma Science Total Liabilities Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Strides Pharma Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (NSE:STAR) » Definitions » Total Liabilities

Traded in Other Exchanges

532531:India

Address

Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076

Website

https://www.strides.com

Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines